| Literature DB >> 34545276 |
Yunpeng Peng1,2, Xiaole Zhu1,2, Chaoqun Hou1,2, Chenyuan Shi1,2, Dongya Huang1,2, Zipeng Lu1,2, Yi Miao1,2, Qiang Li1,2.
Abstract
Several inflammation-related factors (IRFs) have been reported to predict organ failure of acute pancreatitis (AP) in previous clinical studies. However, there are a few shortcomings in these models. The aim of this study was to develop a new prediction model based on IRFs that could accurately identify the risk for organ failure in AP. Methods. 100 patients with their clinical information and IRF data (levels of 10 cytokines, percentages of different immune cells, and data obtained from white blood cell count) were retrospectively enrolled in this study, and 94 patients were finally selected for further analysis. Univariate and multivariate analysis were applied to evaluate the potential risk factors for the organ failure of AP. The area under the ROC curve (AUCs), sensitivity, and specificity of the relevant model were assessed to evaluate the prediction ability of IRFs. A new scoring system to predict the organ failure of AP was created based on the regression coefficient of a multivariate logistic regression model. Results. The incidence of OF in AP patients was nearly 16% (15/94) in our derivation cohort. Univariate analytic data revealed that IL6, IL8, IL10, MCP1, CD3+ CD4+ T lymphocytes, CD19+ B lymphocytes, PCT, APACHE II score, and RANSON score were potential predictors for AP organ failure, and IL6 (P = 0.038), IL8 (P = 0.043), and CD19+B lymphocytes (P = 0.045) were independent predictors according to further multivariate analysis. In addition, a preoperative scoring system (0-11 points) was constructed to predict the organ failure of AP using these three factors. The AUC of the new score system was 0.86. The optimal cut-off value of the new scoring system was 6 points. Conclusions. Our prediction model (based on IL6, IL8, and CD19+ B Lymphocyte) has satisfactory working efficiency to identify AP patients with high risk of organ failure.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34545276 PMCID: PMC8449737 DOI: 10.1155/2021/4906768
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Predictive scoring system for OF.
| Preoperative factor | Points contributed | ||
|---|---|---|---|
| IL 6 (pg/mL) | <7 | 0 | 0 |
| 7-150 | 0.015257141 | 1 | |
| 150-250 | 3 | ||
| >250 | 4 | ||
| IL 8 (pg/mL) | <8.1 | 0 | 0 |
| 8.1-21.3 | 0.248266704 | 2 | |
| >21.3 | 4 | ||
| CD19+ B lymphocyte s(%) | <9 | 0 | 0 |
| 9-14 | 0.122927762 | 1 | |
| >14 | 3 |
Characteristics of enrolled patients.
| Variable | NOF ( | OF ( |
|
|
|---|---|---|---|---|
| Age (years) (mean ± SD) | 50.7 ± 16.3 | 47.1 ± 18.2 | 0.774 | |
| Sex, male/female | 33/46 | 7/8 | 0.821 | |
| Time of onset (hours) | 0.705 | |||
| 0-24 h | 28 | 7 | ||
| 24-48 h | 27 | 4 | ||
| 48-72 h | 24 | 4 | ||
| Etiology | 0.417 | |||
| Biliary, | 43 | 11 | ||
| Alcohol, | 8 | 2 | ||
| Hypertriglyceridemia, | 13 | 1 | ||
| Other, | 15 | 1 | ||
| APPACHE II score | 3.8 ± 2.5 | 5.7 ± 3.2 | 0.011 | |
| RANSON score | 1.1 ± 0.9 | 2.3 ± 9.8 |
| |
| Length of hospital stay (days) | 9 (7, 12) | 16 (15, 36) | -4.06 |
|
| Hospital cost (CNY∗) | 32435 (22203, 41689) | 75075 (62198, 174771) |
| |
| Inflammatory markers (pg/mL) | Median (P25, P75) | Median (P25, P75) | ||
| IL1a | 2.35 (1.55, 4.25) | 1.55 (1.28, 2.56) | -1.76 | 0.474 |
| IL1b | 3.32 (1.73, 8.18) | 3.16 (1.69, 11.38) | -0.03 | 0.895 |
| IL4 | 2.33 (1.42, 4.75) | 2.08 (1.57, 3.67) | -0.49 | 0.431 |
| IL6 | 24.43 (10.18, 42.3) | 106.9 (78.97, 188.13) | -4.82 |
|
| IL8 | 4.52 (2.99, 7.86) | 14.14 (5.68, 18.03) | -3.76 | 0.002 |
| IL10 | 1.51 (0.83, 2.62) | 8.25 (4.33, 14.98) | -4.67 | 0.003 |
| IL13 | 0.58 (0.32, 0.76) | 0.31 (0.2, 0.65) | -1.36 | 0.348 |
| MCP1 | 152.64 (125.18, 192.46) | 234.11 (165.02, 280.94) | -1.01 | 0.001 |
| IFNg | 1.56 (0.93, 2.49) | 1.21 (0.78, 2.24) | -2.71 | 0.505 |
| TNFa | 5.78 (2.34, 11.16) | 4.4 (2.2, 11.55) | -0.45 | 0.624 |
| PCT (ng/mL) | 0.42 (0.12, 1.18) | 2.07 (0.33, 23.38) | -2.65 |
|
| CRP (mg/mL) | 90 (40.1, 90) | 90 (84.9, 90) | -1.02 | 0.84 |
| Routine blood test | ||||
| WBC, ×109/L (mean ± SD) | 10.7 ± 4.1 | 13.3 ± 4.9 | 0.244 | |
| LY, ×109/L median (P25, P75) | 1.13 (0.85, 1.57) | 0.99 (0.85, 1.25) | -1.172 | 0.241 |
| MO, ×109/L median (P25, P75) | 0.53 (0.44, 0.78) | 0.45 (0.34, 0.95) | -0.749 | 0.454 |
| NE, ×109/L (mean ± SD) | 8.7 ± 3.9 | 11.4 ± 4.4 | 0.161 | |
| Immunity markers (%) | ||||
| CD3 T lymphocytes | 67.8 ± 9.5 | 58.6 ± 14.1 | 0.002 | |
| CD3CD4 T lymphocytes | 39.8 ± 10.0 | 31.3 ± 8.3 | 0.007 | |
| CD3CD8 cytotoxic T lymphocytes | 23.06 (17.56, 28.53) | 21.56 (13.21, 26.84) | -1.1 | 0.272 |
| CD16+ CD56+ natural killer cells | 10.9 (6.7, 18.39) | 14.67 (7.63, 17.39) | -0.49 | 0.624 |
| CD19+ B lymphocytes | 14.5 (10.2, 19.8) | 25.57 (17.9, 29.97) | -3.929 |
|
| CD4CD8 cytotoxic T lymphocytes | 1.76 (1.29, 2.24) | 1.55 (1.09, 2.87) | -0.083 | 0.934 |
∗CNY (Chinese Yuan), white blood cell counts (WBC), lymphocyte (LY), neutrophils (NE), and monocyte (MO).
Univariate analyses of factors predicting OF.
| Odds ratio | Std. err. |
| 95% conf. interval | ||
|---|---|---|---|---|---|
| Age | 0.9868881 | 0.0171669 | -0.76 | 0.448 | 0.9538086, 1.021115 |
| Gender | 0.8198758 | 0.4637188 | -0.35 | 0.725 | 0.2705899, 2.484189 |
| APACHE II score | 1.275259 | 0.1280648 | 2.42 | 0.015 | 1.047415, 1.552667 |
| RANSON score | 3.570297 | 1.186867 | 3.83 | <0.001 | 1.860978, 6.849637 |
| IL1a | 0.9204542 | 0.1064778 | -0.72 | 0.474 | 0.7337286, 1.154699 |
| IL1b | 0.9975549 | 0.0183145 | -0.13 | 0.894 | 0.9622973, 1.034104 |
| IL4 | 0.9486596 | 0.0635995 | -0.79 | 0.432 | 0.8318493, 1.081873 |
| IL6 | 1.014311 | 0.0049215 | 2.93 | 0.003 | 1.004711, 1.024003 |
| IL8 | 1.200382 | 0.0638983 | 3.43 | 0.001 | 1.081455, 1.332386 |
| IL10 | 1.263606 | 0.0983619 | 3.01 | 0.003 | 1.084806, 1.471875 |
| IL13 | 0.5039705 | 0.3617765 | -0.95 | 0.34 | 0.123415, 2.057986 |
| MCP1 | 1.011875 | 0.0041537 | 2.88 | 0.004 | 1.003767, 1.020049 |
| IFNg | 0.8752206 | 0.1774049 | -0.66 | 0.511 | 0.5882761, 1.302129 |
| TNFa | 0.9844869 | 0.0314253 | -0.49 | 0.624 | 0.9247815, 1.048047 |
| PCT | 1.144502 | 0.0563309 | 2.74 | 0.006 | 1.039253, 1.260409 |
| CRP | 1.01183 | 0.0111544 | 1.07 | 0.286 | 0.990202, 1.03393 |
| Cause | 0.6276013 | 0.1894851 | -1.54 | 0.123 | 0.3472878, 1.13417 |
| CD3 T lymphocytes | 0.9298539 | 0.0238692 | -2.83 | 0.005 | 0.8842285, 0.9778336 |
| CD3CD4 T lymphocytes | 0.9241535 | 0.0283805 | -2.57 | 0.01 | 0.8701696, 0.9814864 |
| CD3CD8 cytotoxic T lymphocytes | 0.9575243 | 0.0332156 | -1.25 | 0.211 | 0.8945867, 1.02489 |
| CD16+ CD56+ natural killer cells | 1.021315 | 0.032097 | 0.67 | 0.502 | 0.9603039, 1.086201 |
| CD19+ B lymphocytes | 1.110688 | 0.0364459 | 3.2 | 0.001 | 1.041504, 1.184468 |
| CD4CD8 cytotoxic T lymphocytes | 1.050004 | 0.2806481 | 0.18 | 0.855 | 0.6218407, 1.772975 |
| WBC, ×109/L | 1.078487 | 0.0699162 | 1.17 | 0.244 | 0.9498018, 1.224606 |
| LY, ×109/L | 1.516559 | 0.9935976 | 0.64 | 0.525 | 0.4199339, 5.476934 |
| MO, ×109/L | 0.3913318 | 0.253425 | -1.45 | 0.147 | 0.1099791, 1.392451 |
| NE, ×109/L | 1.101204 | 0.0761925 | 1.39 | 0.164 | 0.961552, 1.261138 |
| Ca | 0.0473802 | 0.0504324 | -2.86 | 0.004 | 0.0058825, 0.3816217 |
Multivariate analyses of factors predicting OF.
| Odds ratio | Std. err. |
| 95% conf. interval | ||
|---|---|---|---|---|---|
| RANSON score | 9.380673 | 7.650668 | 2.74 | 0.006 | 1.896762, 46.39328 |
| PCT | 1.099312 | 0.0612663 | 1.7 | 0.089 | 0.9855586, 1.226196 |
| IL6 | 1.015374 | 0.0074628 | 2.08 | 0.038 | 1.000852, 1.030107 |
| IL8 | 1.281802 | 0.1574817 | 2.02 | 0.043 | 1.007494, 1.630794 |
| IL10 | 1.056482 | 0.1449462 | 0.4 | 0.689 | 0.8073833, 1.382434 |
| MCP1 | 0.982185 | 0.0102192 | -1.73 | 0.084 | 0.9623586, 1.00242 |
| CD19+ B lymphocytes | 1.130803 | 0.069377 | 2 | 0.045 | 1.002684, 1.275292 |
predictive value of IRFs model and other clinical factors for OF.
| Preoperative factor | AUC | Std. err. | 95% conf. interval | |
|---|---|---|---|---|
| Lower limit | Upper limit | |||
| APACHEII | 0.684 | 0.072 | 0.541 | 0.826 |
| RANSON | 0.821 | 0.055 | 0.712 | 0.929 |
| IL6 | 0.895 | 0.044 | 0.808 | 0.981 |
| IL8 | 0.808 | 0.056 | 0.699 | 0.916 |
| CD19+ B lymphocytes | 0.821 | 0.047 | 0.729 | 0.913 |
| IFRs | 0.905 | 0.036 | 0.835 | 0.976 |
Figure 1ROC curve analysis of the IRFs and relative clinical factors in prediction of OF.
Figure 2Comparisons of the AUCs between scoring systems in prediction of OF.
Figure 3Mean receiver-operating characteristic (ROC) curve of the new prediction score for prediction of OF in tenfold crossvalidation.